Preparation method of vinorelbine-doxorubicin drug-loaded liposome

By preparing structural phospholipids and blank liposomes rich in short carbon chain fatty acids, the drug-loaded liposomes are formed, which solves the side effects and targeted problems of vinorelbine and doxorubicin in traditional chemotherapy, and improves the biological of the drug Utilization and therapeutic effects enable targeted drug delivery and synergistic therapy.

CN118975986APending Publication Date: 2024-11-19CHANGZHOU JINYUAN PHARM MFG CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411036255.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-31
Publication Date
2024-11-19

AI Technical Summary

Technical Problem

As anti-cancer drugs, vinorelbine and doxorubicin have toxic side effects, bioavailability and targeting problems in traditional chemotherapy, making it difficult to effectively target tumor cells, resulting in poor treatment effects.

Method used

Soy lecithin, ethyl acetate, ethyl propionate, ethyl butyrate and catalyst are used to carry out transesterification reaction to prepare structural phospholipids, combined with polyethylene glycol monomethyl ether sodium salt, lecithin and other materials to prepare blank liposomes, through Ultrasonic crushing and hydration reactions form drug-loaded liposomes, which improves the encapsulation rate and drug loading volume of the drug.

Benefits of technology

It improves the stability and release efficiency of the drug, enhances the targeting and therapeutic effect of the drug, reduces the toxicity to normal tissues, realizes the synergistic therapy of vinorelbine and doxorubicin, and improves the anti-cancer effect.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004971146150000082
    Figure BDA0004971146150000082
  • Figure BDA0004971146150000091
    Figure BDA0004971146150000091
Patent Text Reader

Abstract

The invention relates to the technical field of pharmaceutical preparations, in particular to a preparation method of vinorelbine-doxorubicin drug-loaded liposome. Soybean lecithin, ethyl acetate, ethyl propionate, ethyl butyrate, a catalyst and normal hexane are added to prepare the structural phospholipid. Then, polyethylene glycol monomethyl ether sodium salt, lecithin E80, structural phospholipid, cholesterol, dipalmitoyl phosphatidyl glycerol and distearoyl phosphatidyl ethanolamine-polyethylene glycol 2000 are used as main raw materials, and a blank liposome is prepared; and mixing the drug-loaded solution, the black phosphorus solution and the blank liposome, and carrying out ultrasonic crushing, mixing, stirring and centrifuging to obtain a finished product. The finished product prepared by the invention can effectively improve the drug loading capacity and optimize the performance of a drug delivery system, thereby effectively improving the treatment effect of the combination of the two drugs.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of pharmaceutical preparations, in particular to a method for preparing vinorelbine-doxorubicin drug-loaded liposomes. Background Art

[0002] Drug liposomes are a drug delivery system with great potential. Their modern value lies in that they significantly improve the efficacy, safety and application breadth of drug treatment. Liposomes are tiny vesicles composed of a double-layer phospholipid membrane that can encapsulate drugs and release them at specific sites in the body. On the one hand, drug liposomes can effectively improve the bioavailability of drugs. Many drugs have poor solubility and stability in the body. Liposomes can encapsulate drugs in their inner cavity to prevent the drugs from being rapidly degraded or metabolized in the body, thereby increasing their concentration at the target site. This encapsulation method not only protects the drug, but also enhances its sustained release ability in the body, improving the therapeutic effect. On the other hand, the use of drug liposomes can significantly improve the safety of drugs. The distribution of traditional drugs in the body may cause toxic side effects, while liposome encapsulation can reduce the exposure of drugs to healthy tissues. In this way, the toxicity and side effects of drugs are significantly reduced, improving patient tolerance and overall treatment safety.

[0003] Vinorelbine and doxorubicin are two commonly used anticancer drugs, which are widely used to treat various malignant tumors. However, the clinical application of these drugs often faces a series of challenges, including drug toxicity, drug bioavailability and targeting. Traditional chemotherapy drugs often do not have good targeting in the body, which causes the drugs to act not only on tumor cells, but also on normal tissues, thereby causing serious side effects. Loading vinorelbine and doxorubicin into drug liposomes can achieve targeted delivery through surface modification. The surface of liposomes can bind to specific ligands or antibodies, which can recognize and bind to specific receptors on the surface of tumor cells, thereby delivering drugs directly to the tumor site, reducing toxicity to normal tissues and enhancing the therapeutic effect of drugs. In addition, loading vinorelbine and doxorubicin into liposomes together can achieve drug combination therapy and enhance the anti-cancer effect. This combination therapy can exert the synergistic effect of the two drugs, targeting different tumor cell mechanisms and enhancing the therapeutic effect. The liposome delivery system helps release both drugs simultaneously, ensuring they reach optimal concentrations at the tumor site, thereby improving the overall effectiveness of the treatment.

[0004] In order to overcome the defects of the prior art, the present invention provides a method for preparing vinorelbine-doxorubicin drug-loaded liposomes. Summary of the invention

[0005] The purpose of the present invention is to provide a method for preparing vinorelbine-doxorubicin drug-loaded liposomes to solve the problems in the prior art.

[0006] In order to solve the above technical problems, the present invention provides the following technical solutions:

[0007] The preparation method of vinorelbine-doxorubicin drug-loaded liposomes comprises the following steps:

[0008] Step 1: Evenly mix soybean lecithin, ethyl acetate, ethyl propionate, ethyl butyrate and a catalyst, then add n-hexane, stir thoroughly for 20-30 minutes, and carry out ester exchange reaction at 40-50° C. for 6-8 hours. After the reaction, collect the supernatant by centrifugation, remove the solvent by rotary evaporation, and precipitate with acetone to obtain a crude phospholipid product; then mix the crude phospholipid product with acetone, stir at 2-6° C. to precipitate, centrifuge, and vacuum dry to obtain a structured phospholipid;

[0009] Step 2: dissolving vinorelbine and doxorubicin in deionized water to obtain a drug-loaded solution; dissolving black phosphorus in deionized water to obtain a black phosphorus solution; dissolving polyethylene glycol monomethyl ether sodium salt in deionized water to obtain an aqueous phase; dissolving lecithin E80, structural phospholipids, cholesterol, dipalmitoylphosphatidylglycerol, and distearoylphosphatidylethanolamine-polyethylene glycol 2000 in ether-chloroform to obtain an oil phase; rapidly injecting the aqueous phase into the oil phase, and ultrasonically crushing for 5-7 minutes at a power of 90-100 W to obtain an emulsion; removing the solvent from the emulsion by rotary evaporation, adding PBS buffer and reacting at 55-60° C. for 30-40 minutes, and extruding to obtain blank liposomes after the hydration is completed;

[0010] Step 3: Mix the drug-loaded solution, black phosphorus solution and blank liposomes, and crush them by ultrasonication at a power of 60-70 W for 2-3 hours, and then stir them at 25-30° C. for 10-12 hours. After stirring, remove impurities by centrifugation to obtain the finished product.

[0011] More optimally, in step one, the contents of the various components of the structural phospholipids are: by mass, 0.1-0.2 parts of soybean lecithin, 0.6-0.8 parts of ethyl acetate, 0.4-0.5 parts of ethyl propionate, 0.2-0.3 parts of ethyl butyrate, 0.08-0.10 parts of catalyst, and 2.5-2.8 parts of n-hexane.

[0012] More optimally, the catalyst is Amberlyst-15.

[0013] More optimally, the reaction mass ratio of ethyl acetate, ethyl propionate and ethyl butyrate is (2-3):2:1.

[0014] More optimally, in step 2, the concentration of the drug-loaded solution is 10-12 mg / mL, and the concentration of the black phosphorus solution is 0.20-0.22 mg / mL.

[0015] More optimally, in step 2, the reaction mass ratio of polyethylene glycol monomethyl ether sodium salt, lecithin E80, structural phospholipids, cholesterol, dipalmitoylphosphatidylglycerol, distearoylphosphatidylethanolamine-polyethylene glycol 2000 is 5:(30-35):(15-20):32:14:2.

[0016] More optimally, in step 2, the volume ratio of the water phase to the oil phase is (1.0-1.2):4.

[0017] More optimally, in step 2, the pH of the PBS buffer is 7.5-7.8, and the concentration is 0.010-0.012 mol / L.

[0018] More optimally, in step 2, the particle size of the blank liposome is 180-200 nm.

[0019] More optimally, in step three, the reaction volume ratio of the drug-loaded solution, the black phosphorus solution and the blank liposome is 0.12:2:(3-5).

[0020] Beneficial effects of the present invention:

[0021] The present invention prepares a structural phospholipid by adding soybean lecithin, ethyl acetate, ethyl propionate, ethyl butyrate, a catalyst and n-hexane. Then, polyethylene glycol monomethyl ether sodium salt, lecithin E80, structural phospholipid, cholesterol, dipalmitoylphosphatidylglycerol and distearoylphosphatidylethanolamine-polyethylene glycol 2000 are used as main raw materials to prepare blank liposomes. The drug-loaded solution, the black phosphorus solution and the blank liposomes are mixed, and the finished product is obtained by ultrasonic crushing, mixing and stirring, and centrifugation.

[0022] The present invention is characterized in that, in step one, by adding soybean lecithin, ethyl acetate, ethyl propionate, ethyl butyrate, catalyst, n-hexane, a structured phospholipid is prepared. In this step, under the catalytic action of catalyst Amberlyst-15, soybean lecithin, ethyl acetate, ethyl propionate and ethyl butyrate undergo ester exchange reaction to obtain structured phospholipid. The structured phospholipid prepared by this step is rich in short-chain fatty acids, so on the one hand, the structured phospholipid prepared generally has a lower melting point and higher fluidity, and short-chain fatty acids such as acetic acid (C2), propionic acid (C3) and butyric acid (C4) can effectively reduce the freezing point of phospholipid bilayer, so that phospholipid film still remains liquid at a lower temperature, and this characteristic plays an important role in the fluidity and flexibility of biofilm. On the other hand, in drug delivery systems, the phospholipids rich in short-chain fatty acids can improve the stability and release characteristics of drug liposomes. Due to its higher fluidity and low freezing point, this phospholipid shows excellent fluidity and biocompatibility at body temperature, can improve the release efficiency and bioavailability of drugs, thereby optimizing the performance of drug delivery systems.

[0023] The present invention is characterized in that, in step 2, polyethylene glycol monomethyl ether sodium salt, lecithin E80, structural phospholipids, cholesterol, dipalmitoyl phosphatidyl sugar, distearoyl phosphatidylethanolamine-polyethylene glycol 2000 are used as main raw materials to prepare blank liposomes. In step 2, by adding lecithin E80 and structural phospholipids as the main phospholipid components and interacting with other substances, the prepared blank liposomes have good stability, fluidity and other properties, so it is possible to effectively coat and encapsulate drugs to maintain drug efficacy. In step 3, the drug-loaded solution, black phosphorus solution and blank liposomes are mixed to prepare a finished product. In this step, black phosphorus material has a huge specific surface area, so vinorelbine and doxorubicin drugs can be adsorbed to the black phosphorus surface by ultrasonic stirring, thereby effectively improving the loading amount of vinorelbine and doxorubicin drugs. At the same time, the blank liposomes will be coated and encapsulated with black phosphorus products loaded with vinorelbine and doxorubicin drugs, and finally obtain the finished product. In summary, the prepared finished product has good encapsulation efficiency and drug loading capacity, which can effectively improve the therapeutic effect of the drug. DETAILED DESCRIPTION

[0024] The following will be combined with the embodiments of the present invention to clearly and completely describe the technical solutions in the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0025] Source of raw materials:

[0026] Soybean lecithin, provided by Shanghai Bioengineering Co., Ltd., biologically pure; catalyst Amberlyst-15, provided by Hubei Maidehao Chemical Co., Ltd., model MDH; vinorelbine, provided by Guangzhou Baiyunshan Hanfang Pharmaceutical Co., Ltd.; doxorubicin, provided by Dalian Meilun Biotechnology Co., Ltd.; black phosphorus, provided by Smart-Elements, Austria, model AR; polyethylene glycol monomethyl ether sodium salt, provided by Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, molecular weight 30,000; lecithin E80, provided by Shanghai Dongshang Pharmaceutical Technology Co., Ltd.; cholesterol, provided by Beijing Bailingwei Technology Co., Ltd.; dipalmitoylphosphatidylglycerol, provided by Avite Pharmaceutical Technology Co., Ltd.; distearoylphosphatidylethanolamine-polyethylene glycol 2000, provided by Shanghai Dongshang Pharmaceutical Technology Co., Ltd.; in terms of mass, one portion is 1 g.

[0027] Example 1: Step 1: 0.1 g soybean lecithin, 0.6 g ethyl acetate, 0.4 g ethyl propionate, 0.2 g ethyl butyrate and 0.08 g catalyst Amberlyst-15 were mixed evenly, and then 2.5 g n-hexane was added, and the mixture was stirred for 30 min, and the ester exchange reaction was carried out at 50 ° C for 8 h. After the reaction, the supernatant was collected by centrifugation, the solvent was removed by rotary evaporation, and acetone was precipitated to obtain a crude phospholipid product; the crude phospholipid product was then mixed with acetone, stirred at 6 ° C to precipitate, centrifuged, and vacuum dried to obtain a structured phospholipid;

[0028] Step 2: dissolving vinorelbine and doxorubicin in deionized water to obtain a drug-loaded solution with a concentration of 10 mg / mL; dissolving black phosphorus in deionized water to obtain a black phosphorus solution with a concentration of 0.2 mg / mL;

[0029] 5g of polyethylene glycol monomethyl ether sodium salt was dissolved in deionized water to obtain an aqueous phase; 35g of lecithin E80, 15g of structural phospholipids, 32g of cholesterol, 14g of dipalmitoylphosphatidylglycerol, and 2g of distearoylphosphatidylethanolamine-polyethylene glycol 2000 were dissolved in ether-chloroform to obtain an oil phase; 2mL of the aqueous phase was quickly injected into 8mL of the oil phase, and ultrasonically crushed for 7min at a power of 100W to obtain an emulsion; the emulsion was subjected to rotary evaporation to remove the solvent, and PBS buffer was added to the emulsion for hydration reaction at 60°C for 40min. After the hydration was completed, blank liposomes were obtained by extrusion; wherein the pH of the PBS buffer was 7.5 and the concentration was 0.01mol / L; the particle size of the blank liposomes was 200nm;

[0030] Step 3: Mix 0.12 mL of drug-loaded solution, 0.2 mL of black phosphorus solution and 3 mL of blank liposomes, ultrasonically crush for 3 h at 70 W power, and then stir at 30 ° C for 12 h. After stirring, remove impurities by centrifugation to obtain the finished product.

[0031] Example 2: Step 1: 0.1 g soybean lecithin, 0.6 g ethyl acetate, 0.4 g ethyl propionate, 0.2 g ethyl butyrate and 0.08 g catalyst Amberlyst-15 were mixed evenly, and then 2.5 g n-hexane was added, and the mixture was stirred for 27 min. The ester exchange reaction was carried out at 47 ° C for 7.5 h. After the reaction was completed, the supernatant was collected by centrifugation, the solvent was removed by rotary evaporation, and acetone was precipitated to obtain a crude phospholipid product; the crude phospholipid product was then mixed with acetone, stirred at 5 ° C to precipitate, centrifuged, and vacuum dried to obtain a structured phospholipid;

[0032] Step 2: dissolving vinorelbine and doxorubicin in deionized water to obtain a drug-loaded solution with a concentration of 10 mg / mL; dissolving black phosphorus in deionized water to obtain a black phosphorus solution with a concentration of 0.2 mg / mL;

[0033] 5g of polyethylene glycol monomethyl ether sodium salt was dissolved in deionized water to obtain an aqueous phase; 35g of lecithin E80, 15g of structural phospholipids, 32g of cholesterol, 14g of dipalmitoylphosphatidylglycerol, and 2g of distearoylphosphatidylethanolamine-polyethylene glycol 2000 were dissolved in ether-chloroform to obtain an oil phase; 2mL of the aqueous phase was quickly injected into 8mL of the oil phase, and ultrasonically crushed for 6min at a power of 97W to obtain an emulsion; the emulsion was subjected to rotary evaporation to remove the solvent, and PBS buffer was added to react at 59°C for 37min, and blank liposomes were obtained by extrusion after the hydration was completed; wherein the pH of the PBS buffer was 7.5, and the concentration was 0.01mol / L; the particle size of the blank liposome was 200nm;

[0034] Step 3: Mix 0.12 mL of drug-loaded solution, 0.2 mL of black phosphorus solution and 3 mL of blank liposomes, and crush them by ultrasonication at 67 W for 2.7 h, and then stir them at 29 ° C for 11.5 h. After stirring, remove impurities by centrifugation to obtain the finished product.

[0035] Example 3: Step 1: 0.1 g soybean lecithin, 0.6 g ethyl acetate, 0.4 g ethyl propionate, 0.2 g ethyl butyrate and 0.08 g catalyst Amberlyst-15 were mixed evenly, and then 2.5 g n-hexane was added, and the mixture was stirred for 25 min. The ester exchange reaction was carried out at 45 ° C for 7 h. After the reaction was completed, the supernatant was collected by centrifugation, the solvent was evaporated, and acetone was precipitated to obtain a crude phospholipid product; the crude phospholipid product was then mixed with acetone, stirred at 4 ° C to precipitate, centrifuged, and vacuum dried to obtain a structured phospholipid;

[0036] Step 2: dissolving vinorelbine and doxorubicin in deionized water to obtain a drug-loaded solution with a concentration of 10 mg / mL; dissolving black phosphorus in deionized water to obtain a black phosphorus solution with a concentration of 0.2 mg / mL;

[0037] 5g of polyethylene glycol monomethyl ether sodium salt was dissolved in deionized water to obtain an aqueous phase; 35g of lecithin E80, 15g of structural phospholipids, 32g of cholesterol, 14g of dipalmitoylphosphatidylglycerol, and 2g of distearoylphosphatidylethanolamine-polyethylene glycol 2000 were dissolved in ether-chloroform to obtain an oil phase; 2mL of the aqueous phase was quickly injected into 8mL of the oil phase, and ultrasonically crushed for 6min at a power of 95W to obtain an emulsion; the emulsion was subjected to rotary evaporation to remove the solvent, and PBS buffer was added to react at 57°C for 35min, and blank liposomes were obtained by extrusion after the hydration was completed; wherein the pH of the PBS buffer was 7.5, and the concentration was 0.01mol / L; the particle size of the blank liposome was 200nm;

[0038] Step 3: Mix 0.12 mL of drug-loaded solution, 0.2 mL of black phosphorus solution and 3 mL of blank liposomes, and crush them by ultrasonication at 65 W for 2.5 h, and then stir them at 27 ° C for 11 h. After stirring, remove impurities by centrifugation to obtain the finished product.

[0039] Example 4: Step 1: 0.1 g soybean lecithin, 0.6 g ethyl acetate, 0.4 g ethyl propionate, 0.2 g ethyl butyrate and 0.08 g catalyst Amberlyst-15 were mixed evenly, and then 2.5 g n-hexane was added, and the mixture was stirred for 23 min. The ester exchange reaction was carried out at 43 ° C for 6.5 h. After the reaction was completed, the supernatant was collected by centrifugation, the solvent was removed by rotary evaporation, and acetone was precipitated to obtain a crude phospholipid product; the crude phospholipid product was then mixed with acetone, stirred at 3 ° C to precipitate, centrifuged, and vacuum dried to obtain a structured phospholipid;

[0040] Step 2: dissolving vinorelbine and doxorubicin in deionized water to obtain a drug-loaded solution with a concentration of 10 mg / mL; dissolving black phosphorus in deionized water to obtain a black phosphorus solution with a concentration of 0.2 mg / mL;

[0041] 5g of polyethylene glycol monomethyl ether sodium salt was dissolved in deionized water to obtain an aqueous phase; 35g of lecithin E80, 15g of structural phospholipids, 32g of cholesterol, 14g of dipalmitoylphosphatidylglycerol, and 2g of distearoylphosphatidylethanolamine-polyethylene glycol 2000 were dissolved in ether-chloroform to obtain an oil phase; 2mL of the aqueous phase was quickly injected into 8mL of the oil phase, and ultrasonically crushed for 5min at a power of 93W to obtain an emulsion; the emulsion was subjected to rotary evaporation to remove the solvent, and PBS buffer was added to react at 56°C for 33min, and blank liposomes were obtained by extrusion after the hydration was completed; wherein the pH of the PBS buffer was 7.5, and the concentration was 0.01mol / L; the particle size of the blank liposome was 200nm;

[0042] Step 3: Mix 0.12 mL of drug-loaded solution, 0.2 mL of black phosphorus solution and 3 mL of blank liposomes, and crush them by ultrasonication at 63 W for 2.3 h, and then stir them at 26 °C for 10 h. After stirring, remove impurities by centrifugation to obtain the finished product.

[0043] Example 5: Step 1: 0.1 g soybean lecithin, 0.6 g ethyl acetate, 0.4 g ethyl propionate, 0.2 g ethyl butyrate and 0.08 g catalyst Amberlyst-15 were mixed evenly, and then 2.5 g n-hexane was added, and the mixture was stirred for 20 min, and the ester exchange reaction was carried out at 40° C. for 6 h. After the reaction was completed, the supernatant was collected by centrifugation, the solvent was removed by rotary evaporation, and acetone was precipitated to obtain a crude phospholipid product; the crude phospholipid product was then mixed with acetone, stirred at 2° C. to precipitate, centrifuged, and vacuum dried to obtain a structured phospholipid;

[0044] Step 2: dissolving vinorelbine and doxorubicin in deionized water to obtain a drug-loaded solution with a concentration of 10 mg / mL; dissolving black phosphorus in deionized water to obtain a black phosphorus solution with a concentration of 0.2 mg / mL;

[0045] 5g of polyethylene glycol monomethyl ether sodium salt was dissolved in deionized water to obtain an aqueous phase; 35g of lecithin E80, 15g of structural phospholipids, 32g of cholesterol, 14g of dipalmitoylphosphatidylglycerol, and 2g of distearoylphosphatidylethanolamine-polyethylene glycol 2000 were dissolved in ether-chloroform to obtain an oil phase; 2mL of the aqueous phase was quickly injected into 8mL of the oil phase, and ultrasonically crushed for 5min at a power of 90W to obtain an emulsion; the emulsion was subjected to rotary evaporation to remove the solvent, and PBS buffer was added to react at 55°C for 30min, and blank liposomes were obtained by extrusion after the hydration was completed; wherein the pH of the PBS buffer was 7.5, and the concentration was 0.01mol / L; the particle size of the blank liposome was 200nm;

[0046] Step 3: Mix 0.12 mL of drug-loaded solution, 0.2 mL of black phosphorus solution and 3 mL of blank liposomes, ultrasonically crush for 2 h at 60 W power, and then stir at 25 ° C for 10 h. After stirring, remove impurities by centrifugation to obtain the finished product.

[0047] Comparative Example 1: The reaction mass ratio of ethyl acetate, ethyl propionate, and ethyl butyrate is changed to 1:1:1, and the rest is the same as Example 1, and the specific steps are as follows: Step 1: 0.1g soybean lecithin, 0.2g ethyl acetate, 0.2g ethyl propionate, 0.2g ethyl butyrate and 0.08g catalyst Amberlyst-15 are mixed evenly, and then 2.5g n-hexane is added, and the mixture is stirred for 30min, and the ester exchange reaction is carried out at 50°C for 8h. After the reaction is completed, the supernatant is collected by centrifugation, the solvent is removed by rotary evaporation, and acetone is precipitated to obtain a crude phospholipid product; the crude phospholipid product is then mixed with acetone, stirred at 6°C to precipitate, centrifuged, and vacuum dried to obtain a structured phospholipid;

[0048] Step 2: dissolving vinorelbine and doxorubicin in deionized water to obtain a drug-loaded solution with a concentration of 10 mg / mL; dissolving black phosphorus in deionized water to obtain a black phosphorus solution with a concentration of 0.2 mg / mL;

[0049] 5g of polyethylene glycol monomethyl ether sodium salt was dissolved in deionized water to obtain an aqueous phase; 35g of lecithin E80, 15g of structural phospholipids, 32g of cholesterol, 14g of dipalmitoylphosphatidylglycerol, and 2g of distearoylphosphatidylethanolamine-polyethylene glycol 2000 were dissolved in ether-chloroform to obtain an oil phase; 2mL of the aqueous phase was quickly injected into 8mL of the oil phase, and ultrasonically crushed for 7min at a power of 100W to obtain an emulsion; the emulsion was subjected to rotary evaporation to remove the solvent, and PBS buffer was added to the emulsion for hydration reaction at 60°C for 40min. After the hydration was completed, blank liposomes were obtained by extrusion; wherein the pH of the PBS buffer was 7.5 and the concentration was 0.01mol / L; the particle size of the blank liposomes was 200nm;

[0050] Step 3: Mix 0.12 mL of drug-loaded solution, 0.2 mL of black phosphorus solution and 3 mL of blank liposomes, ultrasonically crush for 3 h at 70 W power, and then stir at 30 ° C for 12 h. After stirring, remove impurities by centrifugation to obtain the finished product.

[0051] Comparative Example 2: The preparation step of the structural phospholipid in step 1 is removed, and the rest is the same as Example 1, and the specific steps are as follows: Step 1: dissolving vinorelbine and doxorubicin in deionized water to obtain a drug-loaded solution with a concentration of 10 mg / mL; dissolving black phosphorus in deionized water to obtain a 0.2 mg / mL black phosphorus solution;

[0052] 5g of polyethylene glycol monomethyl ether sodium salt was dissolved in deionized water to obtain an aqueous phase; 35g of lecithin E80, 32g of cholesterol, 14g of dipalmitoylphosphatidylglycerol, and 2g of distearoylphosphatidylethanolamine-polyethylene glycol 2000 were dissolved in ether-chloroform to obtain an oil phase; 2mL of the aqueous phase was quickly injected into 8mL of the oil phase, and ultrasonically crushed for 7min at a power of 100W to obtain an emulsion; the emulsion was subjected to rotary evaporation to remove the solvent, and then PBS buffer was added to react at 60°C for 40min, and blank liposomes were obtained by extrusion after the hydration was completed; wherein the pH of the PBS buffer was 7.5, and the concentration was 0.01mol / L; the particle size of the blank liposome was 200nm;

[0053] Step 2: 0.12 mL of drug-loaded solution, 0.2 mL of black phosphorus solution and 3 mL of blank liposomes were mixed, ultrasonically crushed at 70 W for 3 h, and then stirred at 30 ° C for 12 h. After stirring, impurities were removed by centrifugation to obtain the finished product.

[0054] Comparative Example 3: The black phosphorus solution in step 3 is removed, and the rest is the same as in Example 1, and the specific steps are as follows: Step 1: 0.1g soybean lecithin, 0.6g ethyl acetate, 0.4g ethyl propionate, 0.2g ethyl butyrate and 0.08g catalyst Amberlyst-15 are mixed evenly, and then 2.5g n-hexane is added, and the mixture is stirred for 30min, and the ester exchange reaction is carried out at 50°C for 8h. After the reaction is completed, the supernatant is collected by centrifugation, the solvent is removed by rotary evaporation, and acetone is precipitated to obtain a crude phospholipid product; the crude phospholipid product is then mixed with acetone, stirred at 6°C to precipitate, centrifuged, and vacuum dried to obtain a structured phospholipid;

[0055] Step 2: dissolving vinorelbine and doxorubicin in deionized water to obtain a drug-loaded solution with a concentration of 10 mg / mL; dissolving 5 g of polyethylene glycol monomethyl ether sodium salt in deionized water to obtain an aqueous phase; dissolving 35 g of lecithin E80, 15 g of structural phospholipids, 32 g of cholesterol, 14 g of dipalmitoylphosphatidylglycerol, and 2 g of distearoylphosphatidylethanolamine-polyethylene glycol 2000 in ether-chloroform to obtain an oil phase; rapidly injecting 2 mL of the aqueous phase into 8 mL of the oil phase, and ultrasonically crushing the emulsion at a power of 100 W for 7 min to obtain an emulsion; removing the solvent from the emulsion by rotary evaporation, and then adding PBS buffer to hydrate the emulsion at 60° C. for 40 min, and extruding the emulsion after hydration to obtain blank liposomes; wherein the pH of the PBS buffer is 7.5, and the concentration is 0.01 mol / L; the particle size of the blank liposomes is 200 nm;

[0056] Step 3: Mix 0.12 mL of drug-loaded solution and 3 mL of blank liposomes, crush by ultrasonication at 70 W for 3 h, and then stir at 30 ° C for 12 h. After stirring, remove impurities by centrifugation to obtain the finished product.

[0057] Detection test:

[0058] Encapsulation efficiency and drug loading test: 1 mL of the finished product was added to 100K Ultra-15 centrifugal filter, centrifuge at 3500rpm for 5min. Then measure 0.5mL of filtrate and add it to a 10mL volumetric flask, add methanol to make up to 10mL. Use HPLC to determine the free drug content in the finished product. Measure 1mL of the finished product and add 10mL of methanol solution, ultrasonicate for 30min, add 6mL of 0.2mol / LHCl-0.9%NaCl solution after demulsification, shake in a 37℃ water bath shaker for 30min, add ammonia water, adjust the pH to 2.5, transfer to a 25mL volumetric flask, put it at 25℃, and add methanol to make up to 25mL. Use HPLC to determine the total drug content in the finished product.

[0059] Finally, the encapsulation efficiency (%) was calculated based on the free drug content and the total drug content, and the drug loading (%) was calculated based on the free drug content, the total drug content and the content of added phospholipids. The results are shown in the following table:

[0060]

[0061]

[0062] Conclusion: The dosage of Examples 1 to 5 remains unchanged, and only some reaction parameters are modified. From the experimental data, it can be seen that the various properties of the samples have no obvious fluctuations.

[0063] Comparative Example 1: The reaction mass ratio of ethyl acetate, ethyl propionate, and ethyl butyrate was changed to 1:1:1, and the rest was the same as Example 1. It can be seen from the experimental data that compared with Example 1, the encapsulation rate was reduced to 65.58%, and the drug loading was reduced to 4.03%. The reasons were analyzed as follows: the reaction mass ratio of ethyl acetate, ethyl propionate, and ethyl butyrate in this application is set to (2-3): 2:1. The structural phospholipids prepared within this reaction range have more short-chain fatty acids. This phospholipid can exhibit excellent fluidity and biocompatibility, and can improve the release efficiency and bioavailability of the drug, thereby optimizing the performance of the drug delivery system and improving the drug loading performance of the drug. Therefore, after adjusting the optimal reaction ratio, the encapsulation rate is reduced and the drug loading is reduced.

[0064] Comparative Example 2: The preparation step of the structured phospholipid in step one is removed, and the rest is the same as Example 1. It can be seen from the experimental data that compared with Example 1, the encapsulation rate is reduced to 62.83%, and the drug loading is reduced to 3.82%. The reason is analyzed as follows: by adding the structured phospholipid of the present application, the fluidity and biocompatibility of the liposomes can be effectively improved, and the release efficiency and bioavailability of the drug can be improved, thereby optimizing the performance of the drug delivery system and improving the drug loading performance of the drug. Therefore, after removing it, the encapsulation rate is reduced and the drug loading is reduced.

[0065] Comparative Example 3: The black phosphorus solution in step 3 is removed, and the rest is the same as Example 1. It can be seen from the experimental data that compared with Example 1, the encapsulation efficiency is reduced to 60.58%, and the drug loading is reduced to 3.72%. The reason is analyzed as follows: black phosphorus has a huge specific surface area, which can effectively increase the surface loading of the drug, thereby further increasing the encapsulation efficiency and drug loading of the drug. Therefore, after the black phosphorus solution is removed, the encapsulation efficiency is reduced and the drug loading is reduced.

[0066] It should be noted that, in this article, relational terms such as first and second, etc. are only used to distinguish one entity or operation from another entity or operation, and do not necessarily require or imply any such actual relationship or order between these entities or operations. Moreover, the terms "include", "comprise" or any other variations thereof are intended to cover non-exclusive inclusion, so that a process method article or device including a series of elements includes not only those elements, but also other elements not explicitly listed, or also includes elements inherent to such process method article or device.

[0067] Finally, it should be noted that the above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art can still modify the technical solutions described in the aforementioned embodiments or replace some of the technical features therein by equivalents. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.

Claims

1. A method for preparing vinorelbine-doxorubicin drug-loaded liposomes, characterized in that: The following steps are involved: Step 1: Evenly mix soybean lecithin, ethyl acetate, ethyl propionate, ethyl butyrate and a catalyst, then add n-hexane, stir thoroughly for 20-30 minutes, and carry out ester exchange reaction at 40-50° C. for 6-8 hours. After the reaction, collect the supernatant by centrifugation, remove the solvent by rotary evaporation, and precipitate with acetone to obtain a crude phospholipid product; then mix the crude phospholipid product with acetone, stir at 2-6° C. to precipitate, centrifuge, and vacuum dry to obtain a structured phospholipid; Step 2: dissolving vinorelbine and doxorubicin in deionized water to obtain a drug-loaded solution; dissolving black phosphorus in deionized water to obtain a black phosphorus solution; dissolving polyethylene glycol monomethyl ether sodium salt in deionized water to obtain an aqueous phase; dissolving lecithin E80, structural phospholipids, cholesterol, dipalmitoylphosphatidylglycerol, and distearoylphosphatidylethanolamine-polyethylene glycol 2000 in ether-chloroform to obtain an oil phase; rapidly injecting the aqueous phase into the oil phase, and ultrasonically crushing for 5-7 minutes at a power of 90-100 W to obtain an emulsion; removing the solvent from the emulsion by rotary evaporation, adding PBS buffer and reacting at 55-60° C. for 30-40 minutes, and extruding to obtain blank liposomes after the hydration is completed; Step 3: Mix the drug-loaded solution, black phosphorus solution and blank liposomes, and crush them by ultrasonication at a power of 60-70 W for 2-3 hours, and then stir them at 25-30° C. for 10-12 hours. After stirring, remove impurities by centrifugation to obtain the finished product.

2. The method for preparing vinorelbine-doxorubicin drug-loaded liposomes according to claim 1, characterized in that: In step 1, the contents of the components of the structural phospholipids are as follows: by mass: 0.1-0.2 parts of soybean lecithin, 0.6-0.8 parts of ethyl acetate, 0.4-0.5 parts of ethyl propionate, 0.2-0.3 parts of ethyl butyrate, 0.08-0.10 parts of a catalyst, and 2.5-2.8 parts of n-hexane.

3. The method for preparing vinorelbine-doxorubicin drug-loaded liposomes according to claim 2, characterized in that: The catalyst is Amberlyst-15.

4. The method for preparing vinorelbine-doxorubicin drug-loaded liposomes according to claim 2, characterized in that: The reaction mass ratio of ethyl acetate, ethyl propionate and ethyl butyrate is (2-3):2:

1.

5. The method for preparing vinorelbine-doxorubicin drug-loaded liposomes according to claim 1, characterized in that: In step 2, the concentration of the drug-loaded solution is 10-12 mg / mL, and the concentration of the black phosphorus solution is 0.20-0.22 mg / mL.

6. The method for preparing vinorelbine-doxorubicin drug-loaded liposomes according to claim 1, characterized in that: In step 2, the reaction mass ratio of polyethylene glycol monomethyl ether sodium salt, lecithin E80, structural phospholipids, cholesterol, dipalmitoylphosphatidylglycerol, and distearoylphosphatidylethanolamine-polyethylene glycol 2000 is 5:(30-35):(15-20):32:14:

2.

7. The method for preparing vinorelbine-doxorubicin drug-loaded liposomes according to claim 1, characterized in that: In step 2, the volume ratio of the water phase to the oil phase is (1.0-1.2):

4.

8. The method for preparing vinorelbine-doxorubicin drug-loaded liposomes according to claim 1, characterized in that: In step 2, the pH of the PBS buffer is 7.5-7.8, and the concentration is 0.010-0.012 mol / L.

9. The method for preparing vinorelbine-doxorubicin drug-loaded liposomes according to claim 1, characterized in that: In step 2, the particle size of the blank liposome is 180-200 nm.

10. The method for preparing vinorelbine-doxorubicin drug-loaded liposomes according to claim 1, characterized in that: In step 3, the reaction volume ratio of the drug-loaded solution, the black phosphorus solution and the blank liposomes is 0.12:2:(3-5).